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Aim: Determination of the physicochemical parameters governing growth factors 
(GFs) adsorption and release from mesoporous calcium phosphate ceramics. Materials 
& methods: Six mesoporous calcium phosphate ceramics prepared by soft and hard 
templating were loaded with two different physiological concentrations of TGF-β1 or 
VEGF165 and their in vitro kinetics of adsorption/release were studied. Results: This low 
GF loading promotes adsorption on the highest binding sites. The usually encountered 
detrimental burst release is thus considerably reduced for samples prepared by hard-
templating method. Conclusion: Our findings highlight that the strong affinity of GFs 
with the ceramic surfaces, demonstrated by a slow GFs release, is enhanced by the 
large surface area, confinement into mesopores of ceramics and high difference of 
surface charge between ceramic surfaces and GFs.
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Calcium phosphate (CaP)-based ceram-
ics, especially like hydroxyapatite (HA), are 
widely used in bone regeneration due to their 
good biocompatibility and resorption capac-
ity [1]. However, the performance of CaP as 
implants can be improved if they are com-
bined with active molecules such as antibiot-
ics or bioactive proteins [2]. The association 
of CaP and growth factors (GFs) is efficient 
for both in vitro and in vivo animal experi-
ments [3,4]. Among GFs, the members of the 
TGF-β superfamily such as bone morpho-
genetic proteins (BMP) have been most fre-
quently used in bone tissue engineering [4,5]. 
Nevertheless, the range of GFs used alone 
and in various combinations for bone tis-
sue engineering is extensive. These include 
BMP-2, BMP-4, BMP-7, FGF-2, TGF-β1, 
TGF-β2, TGF-β3, VEGF, IGF-1, PDGF 
and SDF-1 [4,6]. BMP-2 and BMP-7 clinical 
delivery systems for human applications are 
being currently used for osteoinduction; how-
ever, they are far from being satisfactory [7]. 
Indeed, like other GFs, BMPs are labile with a 
short half-life in vivo. Surface-deposited pro-
teins from functionalized surfaces are released 
too rapidly, in a single high-dose burst [8], 
resulting in dramatic clinical complications 
like ectopic bone formation, abnormal stimu-
lation of bone resorption, etc. [9]. In this work, 
we chose to focus on TGF-β1, a member of the 
TGF family, and VEGF. TGF-β1 is a multi-
functional protein that has a pivotal role in 
bone remodeling as it has effects on both bone 
resorption and formation [10]. Even though 
VEGF is not directly related to bone regenera-
tion, it still helps in stimulating angiogenesis 
and formation of new blood vessels or branch-
ing from existing vessels that are essential for 
bone formation [11]. It has also been shown 
to improve bone maturation when associated 
with  bioactive glass carriers [12].
In previous studies, GFs were either com-
bined with nonporous CaP surfaces or with 
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macroporous scaffolds that featured pores of sev-
eral hundred micrometers in diameter [13–18]. Com-
posite scaffolds associating CaP and biodegradable 
polymers have also been used as a release carrier for 
GFs [19–24]. In this case, simple mixture, co-electro-
spinning, double emulsion or covalent cross-linking 
methods were used to associate GFs with polymer 
and control GFs release with polymer degradation 
rate. However, on pure CaP materials the GFs are 
simply adsorbed onto scaffolds by impregnation from 
solution [14,15,18,20]. They are generally released by 
desorption followed by diffusion in the liquid media. 
A smarter release system was achieved by the encap-
sulation of GFs into CaP through the co-precipita-
tion method as proposed by Wernike et al. [13,25]. The 
authors encapsulated and released VEGF from CaP/
VEGF composites by comparing co-precipitated and 
impregnated samples. The co-precipitation improves 
the immobilization of the GF inside the CaP com-
posite both in terms of adsorbed quantity and limited 
burst release [25].
Here, we chose a different method for the control 
of GF release from porous CaP using pore diameters 
close to the size of the GF molecules. The adsorp-
tion of individual GF molecules by this method in 
each pore should then limit uncontrolled release of 
the biomolecules by desorption–diffusion and link 
the biomolecule release to in vivo dissolution of the 
CaP [18]. As most biomolecules have sizes above 2 
nm, the mesopore range (pores size between 2 and 
50 nm) is targeted for these porous materials. More-
over, mesoporous materials are a promising and easier 
to use alternative as compared with co-precipitated 
HA/GF samples. The powders for these materials can 
be prepared in advance, calcined and stored without 
any precautions (no need for refrigeration or sterile 
conditions) and then sterilized before to be extempo-
raneously impregnated with the GF solution during 
implantation. The interest of mesoporosity for con-
trolling delivery of GFs has largely been demonstrated 
the last 10 years on silica- or bioactive glass-based 
materials [26–32]. Compared with silica-based materi-
als, the development of mesoporous HA is much more 
recent and different preparation routes based on the 
use of soft or hard templates have been developed for 
the same purpose [14,33]. Poh et al. have recently taken 
advantage of this using a mesoporous HA material 
prepared by soft-templating for the controlled release 
of VEGF in in vitro experiments [14]. Nevertheless, 
comparison of results from literature on GFs suffers 
from limitation due to the use of different adsorp-
tion and release protocols and sometimes incomplete 
description of the physicochemical characteristics of 
the tested materials. Moreover, there is a lack of com-
parative studies that focus on GFs adsorption/release 
properties on a panel of mesoporous HA ceramics and 
especially those that are prepared by hard-templating 
process. Thus, the key physical and chemical param-
eters that govern the GF adsorption and release at the 
physiological low concentrations (μg/ml) could be 
examined to increase our understanding of GF release 
from mesoporous CaP and to improve the control of 
loading and releasing steps.
In this study, we investigated the adsorption and 
release of two GFs on a panel of six different meso-
porous CaP ceramics having interparticle and intra-
particle mesoporosity for one of them. We compared 
mesoporous CaP prepared using soft [14] or hard 
templates [33] or by co-precipitation method [25]. The 
versatile synthesis of mesoporous materials allowed 
us to prepare CaP ceramics with tunable physico-
chemical properties such as pore diameter (mesopore 
range), composition (partly carbonate substituted 
HA) and crystallinity (low to high). All materials were 
impregnated with TGF-β1 and VEGF
165
. These GFs 
were chosen because of their good performance upon 
implantation when associated with CaP-based ceram-
ics and their sizes (7 × 5 × 3 nm for TGF-β1 [34] and 
10 × 6 × 3 nm for VEGF
165
) [35] that fit the porosi-
ties of the tested mesoporous materials. The GFs were 
used at two different concentrations (1 μg/ml and 11 
or 20 ng/ml). The high concentration was selected due 
to its good release in vitro [25]. The lower concentra-
tion (ng/ml range) was chosen to fit more closely with 
very low-physiological GF concentration met in blood 
plasma (0.004–0.4 ng/ml and 15–40 ng/ml for VEGF 
and TGF, respectively) [36–41], in interstitial fluid (0.07 
ng/ml for VEGF) [42] and in tissue (0.01 ng/mg of 
TGF in rat fracture callus) [43]. Appropriate analysis 
techniques such as specific antibody binding (ELISA) 
or liquid scintillation were used to determine the GF 
concentrations in the supernatant after adsorption or 
release. These data were cross-verified by quantifying 
the amounts of GFs remaining on the ceramic after its 
digestion in acid.
To our knowledge, this is the first study combining 
a panel of mesoporous CaP with different pore sizes, 
crystallinities and compositions prepared by three dif-
ferent methods using two GFs at two different physio-
logical concentrations. The parameters for a controlled 
in vitro delivery of GF up to 6 days are defined for six 
mesoporous CaP ceramics using established and cali-
brated protocols. We propose that good GFs retention is 
due to their adsorption on the strongest binding energy 
sites of the ceramics. This behavior is believed to be 
promoted by the low surface coverage of GFs on mate-
rials, possible confinement of GFs in the  mesopores and 
high surface charge of the ceramics.
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Materials & methods
Material synthesis & characterization
Six different CaP ceramics were synthesized using 
co-precipitation, soft- and hard-templating methods. 
Samples A and B were obtained by co-precipitation 
starting from calcium hydroxide and ammonium dihy-
drogen phosphate precursor solutions as described pre-
viously [44]. Sample A was freeze-dried before calcina-
tion at 650°C, and sample B was dried in air at 100°C 
before calcination at the same temperature. Sample 
C was obtained using the soft-templating approach 
with calcium pantothenate containing dipotassium 
hydrogen phosphate solutions in the presence of a soft 
template, which was the nonionic surfactant denoted 
Pluronic F127 (PEO
106
PPO
70
PEO
106
) [45]. The result-
ing solid was calcined at 300°C for 12 h. The synthesis 
of the ceramic samples D, E and F was obtained using 
the hard-templating route that has been described pre-
viously [33]. Briefly, samples D, E and F were obtained 
from a sol made from calcium nitrate and triethyl 
phosphite, which was gelified in the presence of meso-
porous solids used as hard templates. Samples D and E 
were synthesized in mesocellular silica foam. In con-
trast to sample D which was only dried at 80°C, sam-
ple E was calcined at 500°C before the silica template 
was removed by NaOH leaching. Sample F was pre-
pared in the presence of a mesoporous carbon replica 
derived from the carbon chemical vapor infiltration of 
silica foam. The carbon was introduced into the foam 
by chemical vapor deposition of propylene. The silica 
template was etched with hydrofluoric acid to isolate 
the carbon that was further used as template. After 
filling it with HA precursors, the carbon template was 
removed by oxidation in air at 500°C.
The zeta potential of the six ceramics was measured 
after soaking the ceramics in water or in a liquid simu-
lating the composition of body fluid by using DMEM, 
which is a cell culture medium containing salts, 
 vitamins, glucose and amino acids.
The XRD diffraction patterns of ceramics were 
recorded on a X’pert MPD (PANalytical S.A.S., 
Limeil-Brevannes, France) using Cu kα-radiation (l = 
1.5406 Å).
Macro- and mesoporosity of the samples were inves-
tigated by mercury intrusion porosimetry technique 
using the Autopore IV from Micromeritics (GA, USA). 
This technique is well adapted for this pore size range 
and is based on the progressive mercury intrusion into 
the material pores under controlled pressure. With the 
assumption that the pores are cylindrical, the applied 
pressure can be converted into the pore diameter by 
using the Washburn equation:
p - cos /r= 2s q ,
where P is the pressure required to force mercury into 
a pore of radius r, γ is the surface tension of mercury 
and θ is the contact angle between mercury and the 
pore walls.
Specific surface areas and mesopore volumes were 
determined by N
2
 physisorption technique (77 K) 
using the Brunauer–Emmett–Teller (BET) and 
Barrett-Joyner-Halenda (BJH) methods (desorption 
isotherm), respectively. Surface area was calculated 
assuming a cylindrical pore shape.
Transmission electron microscopy (TEM) was car-
ried out on a Philips CM200 (Philips, Eindhoven, The 
Netherlands) with an acceleration voltage of 20 kV. 
Samples were prepared by dispersing the powder in 
chloroform using sonication, putting a drop of the dis-
persion onto an observation grid and drying at room 
temperature.
Protein adsorption & release
Model proteins such as bovine serum albumin, lyso-
zyme or cytochrome C are generally used in rela-
tively high concentration to determine adsorption 
isotherms and to evaluate release properties of HA 
ceramics. Considering the expensiveness and low-
physiological concentration of GFs (ng/ml to μg/ml 
range), no adsorption study at high concentration 
was performed here. The amount of GFs adsorbed 
by the ceramics was calculated by the difference of 
protein concentration in the supernatant solution. We 
used different concentrations of each GF that were 
denoted hereafter as high (1 μg/ml for both GFs) and 
low (0.011 μg/ml for VEGF
165
 and 0.02 μg/ml for 
 TGF-β1) concentrations.
High-concentration experiments with detection 
by ELISA
Adsorption
All experiments were performed under sterile condi-
tions. The ceramics were dry sterilized at 130°C for 
90 min. The proteins were purchased from PeproTech 
(Neuilly-Sur-Seine, France) and were used as soon 
as they were received. The GFs were reconstituted 
in 10 mM citric acid solution (pH 3.9) or distilled 
water (pH 6) for TGF-β1 and VEGF
165
, respectively. 
The protein aliquots were stored at -20°C. The pro-
teins were thawed at room temperature and diluted in 
water (VEGF) or citric acid (TGF) to a working con-
centration of 1 μg/ml. The ceramic powder samples 
had masses between 9 and 11 mg and were put into 
1.5 ml microtubes. After that, 300 μl of protein solu-
tion was added to each sample followed by shaking 
at room temperature at 90 r.p.m. using a tumbling 
shaker. After the desired time period, the tubes were 
centrifuged and the supernatant was carefully retrieved 
10.2217/nnm-2017-0158 Nanomedicine (Lond.) (Epub ahead of print) future science group
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using a micropipette. Two samples were used at every 
time point. The protein concentration was determined 
with sandwich ELISA kits obtained from R&D Sys-
tems (Lille, France). The instructions provided by the 
manufacturer were used for each kit. Each experiment 
was performed in duplicate. If all of the protein in the 
solution is adsorbed, then the maximal GF loading 
concentration corresponds to approximately 33 μg/g 
of ceramic.
Release
For the GF release experiments, the adsorption was 
performed priorly for 24 h at room temperature as 
described before. For each GF-adsorbed powder, two 
tubes (10 ± 1 mg) were put in contact with a DMEM 
without phenol red solution (300 μl) for different times 
(0 [referred as washout], 1, 2, 3 days [and 4 days for 
TGF]) and agitated on a tumbling shaker at 90 r.p.m. 
at 24°C. After the desired time period, the two tubes 
were centrifuged at 1200 r.p.m. for 5 min. The super-
natant was retrieved using a micropipette and frozen 
until use in the ELISA assay. Therefore, for high GF 
concentrations, the percentage of release was drawn for 
each time point and curve lines were plotted to guide 
the eye.
Low-concentration experiments with radio-
labeled GFs & detection by liquid scintillation
To evaluate the release of GFs at low concentrations, the 
adsorption experiments were conducted as described 
before but using 125I-labeled GFs instead. The pro-
teins were purchased from PerkinElmer (Courtaboeuf, 
France) with an activity of 185 kBq and stabilized with 
0.25% of bovine serum albumin. The proteins were 
diluted to 2 ml with distilled water (VEGF) or citric 
acid (TGF) to working concentrations of 0.011 μg/ml 
(VEGF) and 0.02 μg/ml (TGF), respectively. For the 
release experiments, a different procedure than previ-
ously described for high concentration was used. Only 
two samples for each powder were adsorbed with radio-
active VEGF and TGF during 20 h (10 mg of HA for 
300 μl of solution at 0.011 and 0.02 μg/ml for VEGF 
and TGF, respectively). These samples were centri-
fuged to remove the GF solution. Then, the powders 
were washed with 300 μl of fresh DMEM and cen-
trifuged immediately. The supernatant was retrieved 
for radioactivity measurement. This supernatant will 
be referred to as ‘washout’ or time 0. Desorptions from 
these loaded samples were measured successively after 
different contact times (4 h, 1, 2, 3 and 6 days) in 
DMEM. With this aim, aliquots of 10 μl were taken 
from the supernatant solutions and mixed with 9 ml of 
Ultima Gold AB scintillation cocktail (Perkin-Elmer, 
Courtaboeuf, France). The concentration was calcu-
lated by referring to the activity of the stock solution 
and by correcting it for radioactive decay. Therefore, 
true cumulative release curves could be drawn for low 
GF concentrations.
Validation of the procedure
The amount of GF absorbed (μg of GF/g of ceramic) 
on the six different powders at the end of the release 
experiments was measured and compared with the val-
ues determined from the supernatants. The powders 
were first separated from the supernatant and allowed 
to dry in ambient air for several days. Then, they were 
transferred into new tubes to separate powders from 
proteins that might have attached to the tube wall. 
Then, the powders were dissolved in 200 μl of 4 M 
HCl. The scintillation liquid was directly added to 
the solutions and measured. The concentration was 
calculated after correction for decay by referring to 
the initial activity of the protein (as indicated by the 
manufacturer). These additional tests were conducted 
with a selection of samples (A, B and D), and TGF-β1 
was used at an initial concentration of 0.02 μg/ml. We 
found that the values of the GF amount still adsorbed 
after 6 days agreed reasonably well with the calculated 
values from the supernatants. The differences were less 
than 20%, which suggested accuracy of the measure-
ments when considering the extremely low concen-
tration and numerous manipulation steps. This also 
confirmed that the fraction of GFs adsorbed on the 
container walls during experiments could be neglected.
Results
Physicochemical characteristics of the ceramic 
samples
The ceramics were characterized by different tech-
niques, and the results are shown in Table 1. All ceram-
ics composed of HA are shown by x-ray diffraction 
(Supplementary Figure 1 in supporting information 
part). Due to the synthesis conditions performed in 
air without CO
2
 removal, carbonate species were also 
detected by infrared (IR) spectroscopy (Supplementary 
Figure 2), suggesting that the HA samples are partly 
substituted with carbonate species. Moreover, when 
carbon templates were used, the calcination in air led 
to a CO
2
-rich atmosphere that promoted the formation 
of carbonate as evidenced on the XRD pattern of sam-
ple F, which showed the presence of minor amounts of 
CaCO
3
. The HA crystallinity is related mainly to the 
calcination temperature, with the lowest long-range 
ordering for sample D prepared at room temperature.
TEM observations evidenced the nanostructure 
nature of CaP crystallites with at least one dimension 
in the range 20–60 nm (Figure 1), revealing different 
morphologies related to the synthesis conditions. We 
10.2217/nnm-2017-0158www.futuremedicine.comfuture science group
Physicochemical regulation of TGF & VEGF delivery from mesoporous calcium phosphate bone substitutes    Research Article
Ta
b
le
 1
. P
h
ys
ic
al
 p
ro
p
er
ti
es
 o
f 
th
e 
m
es
o
p
o
ro
u
s 
ce
ra
m
ic
s 
u
se
d
 f
o
r 
th
is
 s
tu
d
y.
C
er
am
ic
 
(p
ro
ce
ss
)
C
al
ci
n
at
io
n
 
te
m
p
er
at
u
re
 
(°
C
)
S B
E
T 
(m
2
/g
)
M
es
o
p
o
re
 
vo
lu
m
e†
 
(c
m
3
/g
)
M
es
o
p
o
re
 
d
ia
m
et
er
‡  
(n
m
)
M
es
o
p
o
re
 
vo
lu
m
e
§  
(c
m
3
/g
)
M
ai
n
 m
es
o
-
m
ac
ro
p
o
re
 
d
ia
m
et
er
s§
 (
n
m
)
Su
rf
ac
e 
ar
ea
 
(m
2
/g
)§
C
ry
st
al
lin
it
y
¶
C
ry
st
al
lit
e 
si
ze
 (
n
m
)†
†
ζ 
-p
o
te
n
ti
al
 
in
 w
at
er
/i
n
 
D
M
EM
‡‡
 (
m
V
)
A
 
(c
o
-p
re
ci
p
it
at
io
n
 –
 
fr
ee
ze
-d
ry
in
g
)
65
0
43
0.
1
9
0.
14
75
–2
0
0
39
G
o
o
d
10
0*
20
-1
3.
6
/-
4
.1
B
 
(c
o
-p
re
ci
p
it
at
io
n
 –
 
d
ry
in
g
)
65
0
63
0.
2
16
0.
30
3
8
49
G
o
o
d
10
0*
20
-5
.5
/-
1.
8
C
 
(s
o
ft
 t
em
p
la
ti
n
g
)
30
0
16
6
0.
5
17
0.
23
55
–6
50
0
74
M
ed
iu
m
20
0*
50
-8
.6
/n
.p
.§
§
D
 
(h
ar
d
 t
em
p
la
ti
n
g
 
Si
O
2
)
N
o
n
e
9
0
0.
4
14
0.
25
20
–5
4
0
0
50
B
ad
20
–3
0
-1
5.
3
/-
6.
2
E (h
ar
d
 t
em
p
la
ti
n
g
 
Si
O
2
)
50
0
22
0.
1
17
n
.p
n
.p
n
.p
G
o
o
d
4
0
–6
0
-2
3.
3
/-
6.
7
F (h
ar
d
 t
em
p
la
ti
n
g
 C
)
50
0
31
0.
1
12
0.
16
35
–5
3,
0
0
0
39
G
o
o
d
#
30
–7
0
-1
4
.0
/-
10
.7
† D
et
er
m
in
ed
 b
y 
th
e 
N
2 a
ds
or
pt
io
n 
at
 7
7 
K
.
‡
D
et
er
m
in
ed
 b
y 
th
e 
BJ
H
 m
et
ho
d.
§
D
et
er
m
in
ed
 b
y 
H
g 
po
ro
si
m
et
ry
.
¶
M
ai
nl
y 
H
A
 p
ha
se
.
#
Pr
es
en
ce
 o
f 
tr
ac
es
 o
f 
C
aC
O
3.
†
† D
et
er
m
in
ed
 f
ro
m
 T
EM
.
‡
‡
D
M
EM
 is
 a
 c
el
l c
ul
tu
re
 m
ed
iu
m
 c
on
ta
in
in
g 
sa
lts
 (i
nc
lu
di
ng
 0
.4
4 
m
g
/m
l c
al
ci
um
 s
al
ts
 a
nd
 0
.1
 m
g
/m
l o
f 
so
di
um
 p
ho
sp
ha
te
), 
vi
ta
m
in
s,
 g
lu
co
se
 a
nd
 a
m
in
o 
ac
id
s.
§
§
Th
e 
su
rf
ac
e 
ch
ar
ge
 o
f 
th
is
 s
am
pl
e 
w
as
 c
lo
se
 t
o 
0
; t
he
 p
ow
de
r 
ag
gl
om
er
at
ed
 a
nd
 t
he
 v
al
ue
 c
ou
ld
 n
ot
 b
e 
de
te
rm
in
ed
 p
re
ci
se
ly
.
BJ
H
: B
ar
re
tt
-J
oy
ne
r-
H
al
en
da
; H
A
: H
yd
ro
xy
ap
at
ite
; n
.p
.: 
N
ot
 p
er
fo
rm
ed
; T
EM
: T
ra
ns
m
is
si
on
 e
le
ct
ro
n 
m
ic
ro
sc
op
y.
10.2217/nnm-2017-0158 Nanomedicine (Lond.) (Epub ahead of print)
Figure 1. Transmission electronic microscopy micrographs of hydroxyapatite samples. The insert in the image F 
corresponds to the encircled portion and highlights the typical mesofoam morphology of sample F.
Figure 2. Cumulative pore volume and differential intrusion versus mean diameter pore size obtained by mercury 
intrusion porosimetry for samples A, B, C, D and F (see facing page).
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found elongated or flat particles after synthesis by clas-
sical co-precipitation or with soft template (samples A, 
B and C) and rather spherical particles for synthesis 
using mesoporous foam as hard templates (samples 
D, E and F). It is worth noting that only sample F 
obtained from the repeated nanocasting process [33] 
displayed typical mesoporous foam morphology. On 
the contrary, samples D and E showed a ‘negative’ 
 replicated structure of the initial silica foam.
Mercury porosimetry curves of all samples displayed 
one or two upward swings which could be attributed 
to interagglomerate porosity for large pore size values 
(5–6 μm) and to interparticular porosity in the large 
mesopore – small macropore range (20–200 nm) 
owing to the nanostructuration of the CaP particles 
(Figure 2). The data corresponding to the main pore 
sizes, mesopore volumes and surface areas (assum-
ing a cylindrical pore shape) calculated from mercury 
 porosimetry curves are reported in Table 1. 
N
2
 adsorption/desorption at 77 K displayed a type 
IV isotherms as previously published [33] confirming 
the large mesoporous character of all samples and their 
high specific surface areas (S
BET
) related to the small 
particle size of CaP samples (Table 1). Even if discrep-
ancies between N
2
 physisorption and Hg-porosimetry 
can be noticed regarding surface areas due to differ-
ent calculation methods, the same trend is observed 
with the highest surface area for sample C, followed 
by D and B and then A, E and F. Regarding mesopore 
size and volume, Hg-porosimetry is more reliable since 
nitrogen adsorption is not accurate for such large mes-
opore size displayed by all samples. We can note here 
that mesopore diameter fits well with GFs size consid-
ering that only some molecules could be confined into 
each mesopore.
Because these GFs were adsorbed/released in solu-
tion, zeta potentials for ceramic samples were mea-
sured in water and DMEM. The negative values were 
32
1
0
0.1
0.01
0.001
0.0001
1e-05
1e-06
1e-07
10 100 1000 1e + 04 1e + 05 1e + 06
C
u
m
u
la
ti
ve
 p
o
re
 v
o
lu
m
e 
(m
l/g
) Differen
tial in
tru
sio
n
 (m
l/g
/n
m
)
Mean diameter (nm)
1 100 1000 1e + 04 1e + 05 1e + 06
Mean diameter (nm)
10
0
3
2
1
0.01
0.001
0.0001
1e-05
1e-06
1e-07
C
u
m
u
la
ti
ve
 p
o
re
 v
o
lu
m
e 
(m
l/g
) Differen
tial in
tru
sio
n
 (m
l/g
/n
m
)
0.0
1 100 1000 1e + 04 1e + 05 1e + 06
Mean diameter (nm)
10
6
5
4
0
0.01
0.001
0.0001
1e-05
1e-06
1e-07
1 100 1000 1e + 04 1e + 05 1e + 06
C
u
m
u
la
ti
ve
 p
o
re
 v
o
lu
m
e 
(m
l/g
) Differen
tial in
tru
sio
n
 (m
l/g
/n
m
)
Mean diameter (nm)
3
2
1
10
2.5
2.0
1.5
0.01
0.001
0.0001
1e-05
1e-06
1e-07
C
u
m
u
la
ti
ve
 p
o
re
 v
o
lu
m
e 
(m
l/g
) Differen
tial in
tru
sio
n
 (m
l/g
/n
m
)
0.5
1.0
2.0
1.5
1.0
0.0
0.1
0.01
0.001
0.0001
1e-05
1e-06
1e-07
1 100 1000 1e + 04 1e + 05 1e + 06
C
u
m
u
la
ti
ve
 p
o
re
 v
o
lu
m
e 
(m
l/g
) Differen
tial in
tru
sio
n
 (m
l/g
/n
m
)
Mean diameter (nm)
1.0
0.5
10
10.2217/nnm-2017-0158 Nanomedicine (Lond.) (Epub ahead of print)
Figure 3. Adsorption kinetics of VEGF. (A) High initial concentration (1 μg/ml) and (B) low concentration (0.011 
μg/ml). The represented values were averaged over the different measurements and vertical bars represent 
the corresponding standard deviations. The horizontal dotted lines represent the maximum possible amount 
adsorbed. For sake of clarity, experimental values were spread around the different times of adsorption (0, 1, 2, 
4, 6 and 20 h). Curve lines were plotted to guide the eye using the following function f(t) = a*(1-exp(-b*t)) with a 
and b constants and t for the time.
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in agreement with the literature [46] and indicate that 
the IEPs of the HA samples were below the pH of the 
solutions, which were 6 and 7.4 for water and DMEM 
solutions, respectively.
The three lowest zeta potentials were observed for 
samples F, D and E, which also displayed the high-
est dissolution (Table 1). The slight increase in the zeta 
potential in DMEM compared with water was related 
to the higher ionic strength of the solution and the 
associated screening on the double layer.
Adsorption kinetics
Figures 3 & 4 show the adsorption kinetics of the differ-
ent ceramics in contact with VEGF and TGF for high- 
(A) and low- (B) concentrated GF solutions. It is worth 
noting that the use of very low concentrations (up to 1 
μg/ml) and the high surface area of the materials led to 
adsorption with a low surface coverage. A simple calcu-
lation based on the specific surface of the GF and the 
porous characteristics of the powders determined by 
nitrogen physisorption (77 K) shows that 2 and 10% 
of the surface area and mesopore volume, respectively, 
are occupied by the adsorbed GFs at the highest initial 
concentration. Therefore, surface areas and pore vol-
umes are not limiting factors for the adsorption since 
both are in a large excess. As the graphics show, the 
GFs adsorb relatively quickly onto the ceramics and 
the adsorption equilibrium is reached for most of the 
samples after 6 h of contact time with the GF solu-
tions. Supplementary Table 1 shows the amount of 
TGF and VEGF adsorbed by the different ceramics at 
the equilibrium after 8 h (high GF loading) and 20 h 
(low GF loading) of contact with the solutions.
In the case of VEGF (Figure 3), all samples show 
the same performance because they quickly adsorb (1 
h) more than 80% of the VEGF present in the solu-
tion. In the case of TGF (Figure 4), there are differ-
ent adsorption profiles between the powders and also 
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Figure 4. Adsorption kinetics of TGF. (A) High initial concentration (1 μg/ml) and (B) low concentration (0.02 
μg/ml). The represented values were averaged over the different measurements and vertical bars represent 
the corresponding standard deviations. The horizontal dotted lines represent the maximum possible amount 
adsorbed. For sake of clarity, experimental values were spread around the different times of adsorption (0, 1, 2, 
4, 6 and 20 h). Curve lines were plotted to guide the eye using the following function f(t) = a*(1-exp(-b*t)) with a 
and b constants and t for the time.
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between the two loading conditions. Moreover, the 
fractions of TGF adsorbed at the equilibrium are gen-
erally lower than those of VEGF and range from 55 to 
92% (Supplementary Table 1). These features suggest 
that TGF has a slightly lower affinity for the ceram-
ics than VEGF and also a lower kinetics of adsorption 
(equilibration time of 6 h instead of 1 h).
Release kinetics
The burst release must be limited to avoid undesired 
effects of excessively high GF concentrations at the 
implantation site. Therefore, the release kinetics of the 
GFs from the ceramics immersed in culture medium 
were measured and reported in Figures 5 & 6 for VEGF 
and TGF, respectively. To compare the results with 
burst and long-term releases presented in the literature, 
the amounts of GF released within the first 4 and 24 h 
of exposure of the loaded ceramics and at the end of the 
experiments (3 and 6 days according the GF concen-
trations) are reported in Supplementary Tables 2 & 3, 
respectively. These measurements show slow release 
kinetics over a long period of time (6 days) with the 
absence of significant burst release. The main portion 
of GFs remains on the ceramic after prolonged expo-
sure. Minor variations between VEGF and TGF are 
discussed below.
Release of VEGF
For high-concentration VEGF loads, samples D, E and 
F show nearly no release after 3 days while sample C 
show a slightly higher release. Samples A and B show the 
highest release but still retain at least 64% of the initial 
load after 1 day (Figure 5, & Supplementary Tables 2 & 3). 
The cumulative release profiles from the different sam-
ples for lower concentration loads are very similar 
showing low and linear increase (Figure 6). All samples 
retain more than 70% of the initial loading after 6 days 
(Supplementary Table 3).
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Figure 5. Cumulative release profiles into culture medium for TGF and VEGF adsorbed at high-initial concentration 
(1 μg/ml). The represented values were averaged over the different measurements and vertical bars represent 
the corresponding standard deviations. For sake of clarity, experimental values were spread around the different 
times of desorption (0, 1, 2, 3 and 4 days). Curves lines were plotted to guide the eye using the following function 
f(t) = a*(1-exp(-b*t)) with a and b constants and t for the time.
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Release of TGF
For high-concentration TGF loads (Figure 5, & Supple-
mentary Tables 2 & 3), more differences between the 
ceramics were observed with a higher release (0–57%) 
after 3 days. It was previously shown by adsorption 
that TGF exhibits lower affinity toward ceramic sur-
faces than VEGF probably because of the low pH of 
the citrate buffer used to dilute TGF. This finding 
could explain the enhanced release of TGF as both 
releases were performed at the same pH (∼7.4). For 
low-concentration loads, the cumulative release profiles 
are similar for all samples (Figure 6 &  Supplementary 
Table 3).
Discussion
Adsorption
We established a ranking between our ceramic samples 
to investigate the parameters governing the adsorp-
tion and release properties of both GFs with different 
ceramics. This ranking was derived from data reported 
in Supplementary Tables 1–3 and can be found in 
Table 2. The samples that adsorbed the highest amount 
or released the least amount of GFs were ranked first. 
We differentiated between burst release during the first 
day and total release during the whole experimental 
period.
Our study used similar conditions as those described 
in the article of Wernike et al. (same growth factor 
[VEGF] and concentration) [13]. All ceramics that we 
have tested, except sample C, showed higher relative 
VEGF adsorption compared with literature. The rela-
tive adsorbed amount reached values between 96 and 
100%. Our samples adsorbed more than double the 
amount of VEGF measured by Wernicke et al. (>30 
μg/g instead of 14 μg/g). We believe that this differ-
ence is due to the high surface area of our samples and 
their mesopore diameter that fits well with GF size. 
Indeed, Wernike et al. [13] did not comment on the 
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Figure 6. Cumulative release profiles into culture medium for TGF and VEGF adsorbed at low-initial concentration, 
respectively, 0.02 and 0.011 μg/ml.The represented values were averaged over the measurements performed on 
two samples and vertical bars represent the corresponding range of variation. For sake of clarity, experimental 
values were spread around the different times of desorption (0, 1, 2, 3 and 6 days). Curves lines were plotted to 
guide the eye using the following function f(t) = a*(1-exp(-b*t)) + c with a, b and c constants and t for the time.
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mesoporosity of their samples. However, we can rea-
sonably assume that the ceramics used in their experi-
ments do not exhibit any porosity in the nanoscale 
as no templates were used during the synthesis. The 
existing macroscale porosity (150–200 μm) is appro-
priate to support cell growth but does not improve the 
adsorption of GFs.
We have observed a slightly lower affinity of TGF 
to ceramics than VEGF. Both GFs have similar iso-
electric point (IEP) values of 9, and it is proposed that 
these different behaviors are related to the pH and 
ionic strength differences of the GFs solutions used for 
adsorption experiments. It is well known that adsorp-
tion of proteins (e.g., GFs) on HA is mainly based on 
electrostatic interaction between oppositely charged 
species [47]. Thus, the adsorption strength increases 
with the difference in charge between both species. 
Interactions occur here between positively charged 
GFs (pH < IEP) and negatively charged HA samples 
(see ζ – potential values in Table 1). These negative ζ 
values were shifted toward zero by decreasing the pH 
(protonation of the surface) and/or by increasing the 
ionic strength (e.g., comparison of values measured in 
water and DMEM in Table 1). Therefore, the experi-
mental conditions used for TGF (low pH [=3.9] with 
high-ionic strength [addition of citric acid]) lead to 
lower electrostatic interactions and lower adsorption 
strength than VEGF (high pH [=6] with low-ionic 
strength [distilled water]).
Moreover, due to the heterogeneous energetic char-
acter of the surface and because GF-loading experi-
ments are performed at low surface coverage (around 
2% of the surface, below 10% of the mesopore volume, 
as mentioned previously), adsorption is supposed to 
occur preferentially on localized adsorption sites with 
the highest adsorption energies. Since adsorption takes 
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place far from saturation, discrimination of samples, 
usually based on the adsorption capacity at saturation, 
is more difficult. Thus, the adsorption of GFs in our 
experiment is probably governed by a combination of 
factors (surface charge, degree of crystallinity, surface 
chemistry, pore size and morphology) that determines 
the population and energy distribution of adsorption 
sites. Even if it is not undoubtly straightforward to 
identify the key parameters for the adsorption of GFs at 
physiological loading, it appears in this study by com-
paring the different samples displaying all relatively 
high surface area and mesopores that one predominant 
parameter is the surface charge of the HA ceramics.
Release
About GFs release, our HA samples display similar or 
enhanced properties for short- and long-term experi-
ments compared with previous studies. For burst 
release within 24 h, the release ranges from 0 to 43% 
of the initial loading (Supplementary Table 2) with 
almost no detected release of VEGF at high loading 
from samples C, D, E and F. Wernike et al. observed 
a release of 28% of VEGF for their best sample 
obtained by the HA/VEGF co-precipitation tech-
nique (for a similar concentration of 1 μg/ml) [13]. 
Similarly, Poh et al. obtained a release of 15% of 
VEGF after 1 day using a mesoporous HA prepared 
by soft-templating without calcination [14]. We did not 
observe any release after 1 day with sample C prepared 
by the same method but with calcination at 300°C 
(Supplementary Table 2).
From Table 2, we concluded that samples D, E 
and F are the most promising carriers for both GFs. 
All three samples were prepared by hard templating 
and were synthesized from the same precursors. The 
TEM experiments showed that they all display spheri-
cal particles with a peculiar mesofoam morphology 
for the sample F. All three samples are well adapted 
for enhanced adsorption due to the confinement 
effect of the GFs within the inter- and intraparticular 
 mesoporosity.
Moreover, these morphological features could act 
together with the averaged surface charge since the 
samples prepared by hard templating also display the 
most negative ζ-potentials in DMEM (Table 1). There-
fore, they develop the strongest magnitude of electro-
static interactions between the positively charged GFs 
(having similar IEP values) and the negatively charged 
ceramic surfaces. These properties lead to a limited 
initial burst release and long-term release (3–6 days) 
Table 2. Ranking of the different ceramics by adsorption and retention potentials using data from 
Supplementary Tables 1–3.
GF TGF TGF VEGF VEGF Average
Initial 
concentration 
(μg/ml)
1.0 0.02 1.0 0.011  
Adsorption
A 2 4 1 1 1
B 3 6 1 3 4
C 1 3 6 3 4
D 3 2 1 6 2
E 6 4 1 6 6
F 5 1 5 1 2
Release
 Total Burst Total Burst Total Burst Total Burst  
A 6 4 1 2 6 6 4 5 5
B 4 3 4 2 5 6 6 6 6
C 2 6 6 2 4 1 5 3 4
D 3 5 1 1 1 1 3 3 1
E 5 n.d. 2 6 1 1 2 1 3
F 1 1 3 5 1 2 1 1 1
During adsorption, the sample adsorbing the most growth factor is noted 1, the second best is noted 2, etc. For release experiments, the 
sample with the lowest release was ranked 1. Burst release values were measured after soaking the loading samples during 1 day while total 
release values were measured after soaking the loading samples for 3 or 6 days.
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for these materials. This feature was also observed 
after immobilizing biomolecules such as amino acids, 
carboxylic acid or biphosphonates on CaP materials 
to provide stronger electrostatic interactions between 
proteins and CaP [47]. For example, the group of 
Rohanizadeh after functionalizing HA with differ-
ent amino acids demonstrated a higher adsorption of 
the lysozyme, a basic protein like TGF and VEGF, on 
HA particles coated with aspartic acid (Asp-HA) [48]. 
This could be explained in terms of favorable elec-
trostatic interactions since under physiological con-
ditions (pH = 7.4), lysozyme was positively charged 
while Asp-HA was negatively charged because of the 
enhanced negative charge sites (PO
4
3- and additional 
two COO- groups) [48]. Nevertheless, due to the com-
plexity of the GFs/HA system, it is difficult to associ-
ate the adsorption/retention properties with only one 
physical–chemical property such as the average sur-
face charge. As already discussed, all tested ceramics 
display extremely low surface coverage by GF (below 
2%), and due to the inhomogeneous energetic nature 
of the surfaces, the adsorption of the GFs could prefer-
entially take place on the strongest and localized bind-
ing sites of the ceramic. All of these effects reinforce 
the binding strength of GFs with the ceramic surfaces 
and could explain the limited GF release observed for 
our samples.
Conclusion & future perspective
A panel of CaP ceramics obtained by soft/hard tem-
plating and coprecipitation processes were tested for 
the adsorption and delivery of two GFs (TGF and 
VEGF). These templating processes lead to nanostruc-
tured ceramics with high specific surface area (up to 
166 m2/g) and inter- and intraparticular mesoporos-
ity. Low GF loading was targeted to fit with physi-
ologically compatible concentrations and to limit side 
effects due to burst release like the ones described with 
BMPs. Since 58 up to 100% of GF of the initial solu-
tion (1 μg/ml) were loaded on CaP surface after 6 h, 
adsorption may be considered as strong. It is proposed 
that the strong GF affinity for the CaP ceramic sur-
face is related to the low loading of the GFs, which 
promotes the GF adsorption onto the sites having the 
Summary points
Background
•	 The performance of calcium phosphate (CaP) implants can be improved if they are associated with active 
molecules such as growth factors (GFs). Generally, GFs are simply adsorbed onto CaP scaffolds and released by 
desorption. A smarter release system must be developed.
•	 The interest of mesoporosity for controlling delivery of GFs has largely been demonstrated during the last 
10 years on silica- or bioactive glass-based materials. This has not been yet explored on mesoporous CaPs, 
specifically those prepared by hard templating.
•	 The key physical and chemical parameters that govern adsorption and release from mesoporous CaP of low GF 
concentrations (μg/ml) have not been explored yet.
Materials & methods
•	 A panel of six different mesoporous CaP ceramics presenting interparticles mesoporosity was synthesized 
by co-precipitation, soft-templating and hard-templating method. One of them exhibited both inter- and 
intraparticles mesoporosity.
•	 TGF-β1 and VEGF165 were adsorbed at two different concentrations (≤1 μg/ml) and appropriate analysis 
techniques such as specific antibody binding (ELISA) or liquid scintillation were used to determine the GF 
concentrations in the supernatant after adsorption or release.
Results
•	 A strong GF affinity for the CaP ceramic surface was observed. It was related to the lower loading 
concentration, which promoted the GF adsorption onto the adsorption sites having the strongest binding 
energy.
•	 The detrimental burst release that is usually encountered within the first hours of exposure to culture medium 
was found to be considerably lower for some of the tested samples. From 0 to 50% of the initial GF loading 
was released after 3 to 6 days in culture medium.
Discussion/conclusion
•	 It is proposed that the strong GF affinity for the CaP ceramic surface is explained by both the high difference 
in charge between the negatively charged ceramic surface and the positively charged GF and the confinement 
within the mesopores, which further enhances the binding energy, especially for sample F with its unique 
mesofoam morphology.
Future perspective
•	 Our findings suggest a possible control of both TGF and VEGF release by combining ceramic substrates loaded 
with TGF or VEGF in different proportions. The combined delivery of osteogenic and angiogenic factors is 
effectively a promising approach in bone regenerative engineering.
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strongest binding energy because of the high differ-
ence in charge between the negatively charged ceramic 
surface and the positively charged GF, especially for 
VEGF compared with TGF and the confinement 
within the mesopores, which further enhances the 
binding energy, especially for sample F with its unique 
mesofoam morphology.
This finding suggests a possible control of both TGF 
and VEGF release by combining ceramic substrates 
loaded with TGF or VEGF in different proportions. 
The combined delivery of osteogenic and angiogenic 
factors is effectively a promising approach in bone 
regenerative engineering [49,50]. Finally, the complete 
release of the remaining GFs will then occur only 
when the ceramics are dissolved in the patient’s body. 
The coupling of the dissolution of the ceramic upon 
implantation with the release of the GFs is an impor-
tant step forward for bone regenerating systems with 
optimized release control.
Supplementary data
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